Recruiting
Ovarian cancer
RecruitingInvestigationalNo placebo
Study of THEO-260 for Patients with High-Grade Serous or Endometrioid Ovarian Cancer
InvestigationalNo placebo
- Substances:–
Countries:
Spain
Spain- Participants:18–64 years · 65+ years
Find therapies in clinical trials near you – page 2
- recruiting
- 3 961
- countries
- 28
- conditions
- 2 103
3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today
91 trials match your criteria
Recruiting
Ovarian cancer
RecruitingRegistered drugNo placebo
Study Comparing Rinatabart Sesutecan with Other Treatments for Patients with Platinum-Resistant Ovarian Cancer
Registered drugNo placebo
- Substances:Glatiramer AcetatePaclitaxel+4
Countries:
Austria
Austria- Participants:18–64 years · 65+ years
- Substances:Glatiramer Acetate
Recruiting
Ovarian cancer+3
RecruitingRegistered drugNo placebo
Study of Relacorilant, Nab-Paclitaxel, and Bevacizumab for Patients with Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer
Registered drugNo placebo
- Substances:BevacizumabRelacorilant+1
Countries:
Belgium
Belgium- Participants:18–64 years · 65+ years
- Substances:Bevacizumab
Recruiting
Ovarian cancer+18
RecruitingInvestigationalNo placebo
Study on the Effectiveness and Safety of BAY 2927088 for Patients with Advanced Solid Tumors with HER2 Mutations
InvestigationalNo placebo
- Substances:Bay 2927088SEVABERTINIB+1
Countries:
Denmark
Denmark- Participants:18–64 years · 65+ years
- Substances:Bay 2927088
Recruiting
Ovarian cancer
RecruitingRegistered drugNo placebo
Study on Olaparib for Maintenance Therapy in Patients with Newly Diagnosed Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer
Registered drugNo placebo
- Substances:Olaparib
Countries:
Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Olaparib
Recruiting
Ovarian cancer+2
RecruitingRegistered drugNo placebo
Comparison of Niraparib alone versus Niraparib with Bevacizumab in patients with newly diagnosed advanced ovarian cancer after chemotherapy with carboplatin and paclitaxel
Registered drugNo placebo
- Substances:BevacizumabCarboplatin+3
Countries:Belgium
Belgium- Participants:18–64 years · 65+ years
- Substances:Bevacizumab
Recruiting
Ovarian cancer+13
RecruitingInvestigationalNo placebo
Study on Ifinatamab Deruxtecan for Patients with Recurrent or Metastatic Solid Tumors
InvestigationalNo placebo
- Substances:Ifinatamab Deruxtecan
Countries:Belgium
Belgium- Participants:18–64 years · 65+ years
- Substances:Ifinatamab Deruxtecan
Recruiting
Ovarian cancer+2
RecruitingInvestigationalNo placebo
Study on the Safety and Tolerability of TUB-040 for Patients with Platinum-Resistant Ovarian Cancer or Relapsed/Refractory Non-Small Cell Lung Cancer
InvestigationalNo placebo
- Substances:Tub-040
Countries:Belgium
Belgium- Participants:18–64 years · 65+ years
- Substances:Tub-040
Recruiting
Ovarian cancer+5
RecruitingRegistered drugNo placebo
Study for Patients with BRCA Mutated Ovarian, Breast, Pancreatic, Prostate, and Endometrial Cancers Continuing Olaparib Treatment
Registered drugNo placebo
- Substances:Olaparib
Countries:Belgium
Belgium- Participants:18–64 years · 65+ years
- Substances:Olaparib
Recruiting
Ovarian cancer
RecruitingRegistered drugNo placebo
Title: Study of 5-Aminolevulinic Acid for detecting tumor tissue during surgery in patients with ovarian cancer
Registered drugNo placebo
- Substances:Aminolevulinic Acid Hydrochloride
Countries:
Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Aminolevulinic Acid Hydrochloride
Recruiting
Ovarian cancer
RecruitingRegistered drugNo placebo
Study of Pembrolizumab with Etoposide and Cisplatin for First-Line Treatment in Patients with Small Cell Ovarian Cancer
Registered drugNo placebo
- Substances:CisplatinCyclophosphamide+3
Countries:
France
France- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Cisplatin
Recruiting
Ovarian cancer+4
RecruitingRegistered drugNo placebo
Study on zAvatar Test for Treatment Decisions in Relapsed Ovarian Cancer and Metastatic Breast Cancer Using Palbociclib and Drug Combination for Eligible Patients
Registered drugNo placebo
- Substances:AbemaciclibAlpelisib+26
Countries:
Portugal
Portugal- Participants:18–64 years · 65+ years
- Substances:Abemaciclib